Collagen Matrix announced that the company has been selected to participate in the U.S. Food and Drug Administration (FDA) Experiential Learning Program (ELP).
The program is designed to provide the FDA's Center for Devices and Radiological Health (CDRH) review staff with real-world experience in the design, manufacture, and use of medical devices, according to the company.
Collagen Matrix's site visit proposal was selected for this year's ELP training in response to the FDA's request for industry participation, specifically in the area of bone grafting materials for dental applications.
"We are pleased to be among the companies selected to participate in the ELP to provide FDA reviewers with a view of the proprietary design, development, and manufacture of collagen- and mineral-based medical devices from industry's perspective," stated Bart Doedens, CEO of Collagen Matrix, in a press release.
